Product Description
Mechanisms of Action: CD80 Binder, CD86 Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: XTL
Company Location: NEW YORK NY 10016
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis B
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2004-000501-21 | P2 |
Completed |
Hepatitis B |
2005-08-30 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|